OPN-375

Phase 3Small molecule

OPN-375 is one of 43 small molecule programs targeting Chronic Rhinosinusitis Without Nasal Polyps. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Rhinosinusitis Without Nasal PolypsActive, not recruiting

Chronic RhinosinusitisActive, not recruiting

Chronic Rhinosinusitis Without Nasal PolypsPhase 3

Active, not recruiting

Chronic RhinosinusitisPhase 3

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Chronic Rhinosinusitis

#DrugCompanyPhaseTrials

Flovent

GSK

Phase 3

2 2

Cinqair

Teva

Phase 3

2 3

Tezspire

AstraZeneca

Phase 3

1 4

Nurtec

Pfizer

Phase 3

1 5

Levaquin

WWim Janssens

Phase 3

2 6

PULMOZYME

Roche

Phase 3

1 7

Oxycontin

PProtega

Phase 3

1 8

Advil

KKenvue Brands

Phase 3

1 9

Fasenra

AstraZeneca

Phase 2

2 10

CM310

KKeymed Biosciences Co.Ltd

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Chronic Rhinosinusitis Without Nasal Polyps

NCT06850805

Clinical

Trials by Indication[1]

Chronic Rhinosinusitis2 trials

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis Without the Presence of Nasal Polyps

Completed·OOptinose US Inc.·Phase 3·NCT03960580·223 enrolled

Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps

Completed·OOptinose US Inc.·Phase 3·NCT03781804·332 enrolled

Chronic Rhinosinusitis Without Nasal Polyps1 trial

Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps

Recruiting·OOptinose US Inc.·Phase 3·NCT06850805·84 enrolled

Efficacy and Safety1 trial

OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps

Recruiting·OOptinose US Inc.·Phase 3·NCT03747458·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for OPN-375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OPN-375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OPN-375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Optinose US Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: OOptinose US Inc.

OPN-375

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Chronic Rhinosinusitis2 trials

Chronic Rhinosinusitis Without Nasal Polyps1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News